ArticleDermatology and therapy2026
Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitiligo is a chronic depigmenting autoimmune skin disease that may be associated with a significant quality-of-life burden and psychosocial comorbidities. Reliable and comparable prevalence rates are critical in building an evidentiary foundation for understanding the full landscape of vitiligo disparities. This study aimed to assess the prevalence of vitiligo among adults in the USA and in five European countries (5EU; France, Germany, Italy, Spain, and the UK).
methodsThis study used data from the 2024 US and 5EU National Health and Wellness Survey (NHWS), a population based, self-reported, syndicated cross-sectional survey of adults (age ≥ 18 years). Respondents were recruited from large internet panels and completed the survey online. Results were weighted to reflect demographic distributions of the general adult population in each country. Self-reported prevalences of ever experiencing vitiligo or having vitiligo diagnosed by a clinician and proportions of patients having had a healthcare provider visit in the last 6 months were reported.
resultsData from 75,013 participants in the USA and 62,022 in Europe were included. The prevalence of adults self-reporting that they ever experienced vitiligo was 2.3% in the USA and 2.0% in Europe (France, 1.7%; Germany, 2.0%; Italy, 2.3%; Spain, 2.2%; UK, 2.1%). The prevalence of adults self-reporting a clinical diagnosis of vitiligo was 0.77% in the USA and 0.76% in Europe (France, 0.73%; Germany, 0.73%; Italy, 0.85%; Spain, 0.89%; UK, 0.65%). The proportion of adults with clinically diagnosed vitiligo who self-reported a dermatologist visit in the past 6 months was 30.7% in the USA and 22.8% in Europe.
conclusionsThis study of adults in the USA and Europe, which used self-reported data collected from the 2024 NHWS, found that the prevalence of self-reported vitiligo was 1.7-2.3%, and the prevalence of self-reported clinically diagnosed vitiligo was 0.65-0.89%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.